A detailed history of Stanley Druckenmiller (Duquesne Family Office LLC) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Duquesne Family Office LLC holds 42,965 shares of PCVX stock, worth $3.69 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
42,965
Holding current value
$3.69 Million
% of portfolio
0.17%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$70.52 - $117.12 $3.03 Million - $5.03 Million
42,965 New
42,965 $4.91 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.1B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track Stanley Druckenmiller's Portfolio

Track Stanley Druckenmiller Portfolio

Follow Stanley Druckenmiller (Duquesne Family Office LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

News

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.